Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy

References

• Hoffman R. Hematology : Basic Principles and Practice. 6th. EBook Collection (EBSCOhost). Philadelphia, PA: Churchill Livingstone; 2013.
   Google Scholar
• Longo DL, Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;12(373):1136–1152. doi:10.1056/NEJMra1406184
   Google Scholar
• Bose P, Vachhani P, Cortes JE. Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat Options Oncol. 2017;18:3. doi:10.1007/s11864-017-0456-2
   PubMed Web of Science ®Google Scholar
• Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015;126(3):319–327. doi:10.1182/blood-2014-10-551911
   PubMed Web of Science ®Google Scholar
• Buege MJ, DiPippo AJ, DiNardo CD. Evolving treatment strategies for elderly leukemia patients with IDH mutations. Cancers (Basel). 2018;10(6):1–20. doi:10.3390/cancers10060187
   Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–732. doi:10.1182/blood-2017-04-779405
   PubMed Web of Science ®Google Scholar
• Scott LJ, Kim ES. Enasidenib: first global approval. Drugs. 2017;77:1705–1711. doi:10.1007/s40265-018-0861-2
   PubMed Web of Science ®Google Scholar
• Dhillon S. Ivosidenib: first global approval. Drugs. 2018;78(14):1509–1516. doi:10.1007/s40265-018-0978-3
   PubMed Web of Science ®Google Scholar
• Bergua JM, Montesinos P, Martinez-Cuadrón D, et al. A prognostic model for survival after salvage treatment with FLAG-Ida +/− gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. Br J Haematol. 2016;174(5):700–710. doi:10.1111/bjh.14107
   PubMed Web of Science ®Google Scholar
• Fridle C, Medinger M, Wilk MC, et al. Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML). Leuk Lymphoma. 2017;58(5):1068–1075. doi:10.1080/10428194.2016.1235274
   PubMed Web of Science ®Google Scholar
• Itzykson R, Thépot S, Berthon C, et al. Azacitidine for the treatment of relapsed and refractory AML in older patients. Leuk Res. 2015;39(2):124–130. doi:10.1016/J.LEUKRES.2014.11.009
   PubMed Web of Science ®Google Scholar
• Abboud CN, Altman JK, Lurie RH, et al. NCCN guidelines version 2.2018 acute myeloid leukemia; 2018. Available from: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Accessed September 4, 2018.
   Google Scholar
• Estey E, Grimwade D, Amadori S, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08
   PubMed Web of Science ®Google Scholar
• Ossenkoppele G, Owenberg BL. How I treat the older patient with acute myeloid leukemia. Blood. 2015;125(5):767–773. doi:10.1182/blood-2014
   PubMed Web of Science ®Google Scholar
• Levis M. Midostaurin approved for FLT3-mutated AML. Blood. 2017;129(26):3403–3406. doi:10.1182/blood-2017-05-782292
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Bernstein ID. Gemtuzumab ozogamicin for acute myeloid leukemia. Blood. 2017;130(22):2373–2376. doi:10.1182/blood-2017-09-797712
   PubMed Web of Science ®Google Scholar
• DeStefano C, Hourigan CS. Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice. Ther Adv Hematol. 2018;9(5):109–121. doi:10.1177/https
   PubMed Web of Science ®Google Scholar
• Nassereddine S, Lap CJ, Haroun F, Tabbara I. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia. Ann Hematol. 2017;96(12):1983–1991. doi:10.1007/s00277-017-3161-0
   PubMed Web of Science ®Google Scholar
• Marcucci G, Maharry K, Wu Y-Z, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2010;28(14):2348–2355. doi:10.1200/JCO.2009.27.3730
   PubMed Web of Science ®Google Scholar
• Molenaar RJ, Thota S, Nagata Y, et al. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia. 2015;29(11):2134–2142. doi:10.1038/leu.2015.91
   PubMed Web of Science ®Google Scholar
• Rakheja D, Konoplev S, Jeffrey Medeiros L, Chen W. IDH mutations in acute myeloid leukemia. Hum Pathol. 2012;43(10):1541–1551. doi:10.1016/j.humpath.2012.05.003
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553–567. doi:10.1016/j.ccr.2010.11.015
   PubMed Web of Science ®Google Scholar
• Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010;116(12):2122–2126. doi:10.1182/blood-2009-11-250878
   PubMed Web of Science ®Google Scholar
• Dinardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732–736. doi:10.1002/ajh.24072
   PubMed Web of Science ®Google Scholar
• Gagné LM, Boulay K, Topisirovic I, Huot M-É, Mallette FA. Oncogenic activities of IDH1/2 mutations: from epigenetics to cellular signaling. Trends Cell Biol. 2017;27(10):738–752. doi:10.1016/j.tcb.2017.06.002
   PubMed Web of Science ®Google Scholar
• Rampal R, Alkalin A, Madzo J, et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 2014;9(5):1841–1855. doi:10.1016/J.CELREP.2014.11.004
   PubMed Web of Science ®Google Scholar
• Rossi G, Minervini MM, Carella AM, Melillo L, Cascavilla N. Wilms’ tumor gene (WT1) expression and minimal residual disease in acute myeloid leukemia. In: van den Heuvel-Elbrink MM, editor. Wilms Tumor. Brisbane (AU): Codon Publications; 2016. Chapter 16. doi10.15586/CODON.WT.2016.CH16
   Google Scholar
• Galkin M. Hypermethylation phenotype diagram. Available from: https://creately.com/diagram/jsik7n4c2/sGaiuyqFW7YUEfuaD656oTBA%3D. Accessed February 24, 2019.
   Google Scholar
• Martínez-Laperche C, Kwon M, Franco-Villegas AC, et al. Wilms tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish group for molecular biology in haematology. Br J Haematol. 2018;181(4):542–546. doi:10.1111/bjh.14635
   PubMed Web of Science ®Google Scholar
• Frairia C, Aydin S, Audisio E, et al. Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: a retrospective cohort study. Leuk Res. 2017;61:10–17. doi:10.1016/J.LEUKRES.2017.08.008
   PubMed Web of Science ®Google Scholar
• Patel KP, Ravandi F, Ma D, et al. Acute myeloid leukemia with IDH1 or IDH2 mutation frequency and clinicopathologic features. Am J Clin Pathol. 2011;135:35–45. doi:10.1309/AJCPD7NR2RMNQDVF
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017;31:272–281. doi:10.1038/leu.2016.275
   PubMed Web of Science ®Google Scholar
• Yen K, Travins J, Wang F, et al. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 2017;7(5):478–493. doi:10.1158/2159-8290.CD-16-1034
   PubMed Web of Science ®Google Scholar
• NCT02577406. An efficacy and safety study of AG-221 (CC-90007) versus conventional care regimens in older subjects with late stage acute myeloid leukemia harboring an isocitrate dehydrogenase 2 mutation. ClinicalTrials.gov. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02577406?term=enasidenib+OR+Ag221&rank=10. Published 2018. Accessed October 3, 2018.
   Google Scholar
• Dalle IA, Dinardo CD. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia. Ther Adv Hematol. 2018;9(7):163–173. doi:10.1177/https
   PubMed Web of Science ®Google Scholar
• IDHIFA Full Prescribing Information. 2017: 1–17. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf. Accessed April 18, 2019.
   Google Scholar
• Stein EM, DiNardo CD, Fathi AT, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019;133(7):676–687. doi:10.1182/blood-2018-08-869008
   PubMed Web of Science ®Google Scholar
• Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916–1924. doi:10.3324/haematol.2012.066100
   PubMed Web of Science ®Google Scholar
• NCT03290443. A study to assess the pharmacokinetics of Enasidenib (CC-90007) in subjects with moderate and severe hepatic impairment. ClinicalTrials.gov. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03290443?term=enasidenib+OR+Ag221&draw=2&rank=2. Published 2018. Accessed October 3, 2018.
   Google Scholar
• Fathi AT, DiNardo CD, Kline I, et al. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2. JAMA Oncol. 2018:1–5. doi:10.1001/jamaoncol.2017.4695.
   PubMed Web of Science ®Google Scholar
• Rogers JE, Yang D. Differentiation syndrome in patients with acute promyelocytic leukemia. J Oncol Pharm Pract. 2011;18(1):109–114. doi:10.1177/1078155211399163
   PubMedGoogle Scholar
• Kc B, Dinardo CD. Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120. Clin Lymphoma Myeloma Leuk. 2016;16(8):460–465. doi:10.1016/j.clml.2016.04.006
   PubMed Web of Science ®Google Scholar
• Norsworthy KJ, Mulkey F, Ward AF, et al. Incidence of differentiation syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for treatment of patients with Relapsed or Refractory (R/R) isocitrate dehydrogenase (idh)1- or idh2-mutated acute myeloid leukemia (aml): a systematic analysis by the U.S. food and drug administration (FDA). Blood. 2018;132(Suppl1):288. doi:10.1182/BLOOD-2018-99-117426
   Google Scholar
• BRIEF-Celgene says monthly wholesale acquisition cost of AML treatment Idhifa is $24,872. Reuters. Available from: https://www.reuters.com/article/brief-celgene-says-monthly-wholesale-acq/brief-celgene-says-monthly-wholesale-acquisition-cost-of-aml-treatment-idhifa-is-24872-idUSFWN1KN0SD. Published 2017. Accessed September 18, 2018.
   Google Scholar
• Prices I, Coupons & patient assistance programs. Drugs.com. Available from: https://www.drugs.com/price-guide/idhifa. Accessed September 18, 2018.
   Google Scholar
• Access and Support Resources & Celgene Patient Support. Idhifa . Available from: https://idhifapro.com/access-and-support/#access-and-reimbursement. Accessed September 18, 2018.
   Google Scholar
• Intlekofer AM, Shih AH, Wang B, et al. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature. 2018;559(7712):125–129. doi:10.1038/s41586-018-0251-7
   PubMed Web of Science ®Google Scholar
• Harding JJ, Lowery MA, Shih AH, et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discov. 2018;8(12):1540–1547. doi:10.1158/2159-8290.CD-18-0877
   PubMed Web of Science ®Google Scholar
• Quek L, David M, Kennedy A, et al. Clonal heterogeneity in differentiation response and resistance to the IDH2 inhibitor Enasidenib in acute myeloid leukemia. Blood. 2017;130(Suppl1). Available from: http://www.bloodjournal.org/content/130/Suppl_1/724. Accessed, 2018.
   PubMedGoogle Scholar
• NCT02632708. Safety study of AG-120 or AG-221 in combination with induction and consolidation therapy in patients with newly diagnosed acute myeloid leukemia with an IDH1 and/or IDH2 mutation. ClinicalTrials.gov. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02632708?term=enasidenib+OR+Ag221&draw=2&rank=12. Accessed October 3, 2018.
   Google Scholar
• Stein E, DiNardo CD, Mims AS, et al. Ivosidenib or Enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions. Blood. 2018;132(Suppl 1):560.
   Google Scholar
• NCT02677922. A safety and efficacy study of oral AG-120 plus subcutaneous azacitidine and oral AG-221 plus subcutaneous azacitidine in subjects with newly diagnosed Acute Myeloid Leukemia (AML). ClinicalTrials.gov. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02677922?term=enasidenib+OR+Ag221&draw=2&rank=11. Published 2018. Accessed October 3, 2018.
   Google Scholar
• Dinardo CD, Stein AS, Stein EM, et al. Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML). J Clin Oncol. 2018;36(15_suppl):7042. doi:10.1200/JCO.2018.36.15_suppl.7042
   Web of Science ®Google Scholar
• NCT03683433. Enasidenib and azacitidine in treating patients with recurrent or refractory acute myeloid leukemia and idh2 gene mutation. ClinicalTrials.gov. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03683433?term=enasidenib+OR+Ag221&rank=9. Published 2018. Accessed October 3, 2018.
   Google Scholar
• NCT03515512. IDH2 inhibition using enasidenib as maintenance therapy for IDH2-mutant myeloid neoplasms following allogeneic stem cell transplantation. ClinicalTrials.gov. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03515512?term=enasidenib+OR+Ag221&rank=4. Published 2018. Accessed October 3, 2018.
   Google Scholar
• Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21(2):178–184. doi:10.1038/nm.3788
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Pratz KW, Jonas BA, et al. Venetoclax in combination with hypomethylating agents induces rapid, deep, and durable responses in patients with AML ineligible for intensive therapy. Blood. 2018;132(Suppl 1):285. doi:10.1182/BLOOD-2018-99-117179
   Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. doi:10.1182/blood-2018-08-868752
   PubMed Web of Science ®Google Scholar
• Molenaar RJ, Maciejewski JP, Wilmink JW, van Noorden CJF. Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene. 2018;37(15):1949–1960. doi:10.1038/s41388-017-0077-z
   PubMed Web of Science ®Google Scholar
• Burd A, Levine RL, Shoben A, et al. Initial report of the beat AML umbrella study for previously untreated AML: evidence of feasibility and early success in molecularly driven phase 1 and 2 studies. Blood. 2018;132(Suppl1):559. doi:10.1182/BLOOD-2018-99-118494
   PubMedGoogle Scholar
• Stein EM, Shoben A, Borate U, et al. Enasidenib is highly active in previously untreated idh2 mutant AML: early results from the beat AML master trial. Blood. 2018;132(Suppl1):287. doi:10.1182/BLOOD-2018-99-118287
   Google Scholar
• Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189–1199. doi:10.1056/NEJMoa1716863
   PubMed Web of Science ®Google Scholar